2021
Effects of canagliflozin on human myocardial redox signalling: clinical implications
Kondo H, Akoumianakis I, Badi I, Akawi N, Kotanidis CP, Polkinghorne M, Stadiotti I, Sommariva E, Antonopoulos AS, Carena MC, Oikonomou EK, Reus EM, Sayeed R, Krasopoulos G, Srivastava V, Farid S, Chuaiphichai S, Shirodaria C, Channon KM, Casadei B, Antoniades C. Effects of canagliflozin on human myocardial redox signalling: clinical implications. European Heart Journal 2021, 42: 4947-4960. PMID: 34293101, PMCID: PMC8691807, DOI: 10.1093/eurheartj/ehab420.Peer-Reviewed Original ResearchConceptsNADPH oxidase activityMyocardial redoxHuman cardiomyocytesNOS couplingAtrial tissueSodium-glucose cotransporter 2 inhibitorsMyocardial NADPH oxidase activityRight atrial appendage biopsiesNitric oxide synthase uncouplingCotransporter 2 inhibitorsEffects of canagliflozinHeart failure patientsBeneficial cardiac effectsExpression of inflammationRecent clinical trialsAMP kinaseHuman atrial tissueOxidase activityPrimary human cardiomyocytesAnti-apoptotic effectsTetrahydrobiopterin bioavailabilityCardiovascular outcomesCardiac effectsFailure patientsCardiac surgery
2018
Heart transplantation versus left ventricular assist devices as destination therapy or bridge to transplantation for 1-year mortality: a systematic review and meta-analysis.
Theochari CA, Michalopoulos G, Oikonomou EK, Giannopoulos S, Doulamis IP, Villela MA, Kokkinidis DG. Heart transplantation versus left ventricular assist devices as destination therapy or bridge to transplantation for 1-year mortality: a systematic review and meta-analysis. Annals Of Cardiothoracic Surgery 2018, 7: 3-11. PMID: 29492379, PMCID: PMC5827119, DOI: 10.21037/acs.2017.09.18.Peer-Reviewed Original ResearchDestination therapyLate mortalityVentricular assist deviceHeart transplantationAssist deviceAvailable studiesSystematic reviewAdvanced heart failure patientsLVAD destination therapyHeart failure patientsCochrane CENTRAL databasesMeta-Analyses (PRISMA) guidelinesPreferred Reporting ItemsRandom-effects modelBTT-LVADCause mortalityFailure patientsMortality benefitAdvanced HFInvasive managementOptimal treatmentDT LVADPooled estimatesHTxReporting Items